Showing results (271-280 of 301) with videos related to

Sort By:
Pageof 31
Applied Optics|June 18, 2010
Comparison of the properties of titanium dioxide films prepared by various techniquesJ M Bennett, E Pelletier, G Albrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemiaB D Cheson, P A Cassileth, D R Head, et al.
Leukemia & Lymphoma|September 1, 1993
Recommended procedures for the classification of acute leukaemias. International Council for Standardization in Haematology (ICSH)C S Scott, G J Den Ottolander, D Swirsky, et al.
Leukemia & Lymphoma|January 1, 1995
Recommended procedures for the classification of acute leukaemiasC S Scott, G J Den Ottolander, D Swirsky, et al.
Leukemia|January 1, 1992
Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology GroupP A Cassileth, J W Andersen, J M Bennett, et al.
American Journal of Hematology|November 1, 1988
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working groupB D Cheson, J M Bennett, K R Rai, et al.
Cancer|October 1, 1983
Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphomaG J Johnson, W G Costello, M M Oken, et al.
The New England Journal of Medicine|December 3, 1998
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remissionP A Cassileth, D P Harrington, F R Appelbaum, et al.
Blood|October 26, 2000
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatinI W Flinn, K J Kopecky, M K Foucar, et al.
Leukemia|October 14, 2014
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)T P Loughran, L Zickl, T L Olson, et al.
Pageof 31